HRP20030792A2 - DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II - Google Patents

DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II

Info

Publication number
HRP20030792A2
HRP20030792A2 HR20030792A HRP20030792A HRP20030792A2 HR P20030792 A2 HRP20030792 A2 HR P20030792A2 HR 20030792 A HR20030792 A HR 20030792A HR P20030792 A HRP20030792 A HR P20030792A HR P20030792 A2 HRP20030792 A2 HR P20030792A2
Authority
HR
Croatia
Prior art keywords
phenyl
methyl
tert
amino
butyl ester
Prior art date
Application number
HR20030792A
Other languages
English (en)
Croatian (hr)
Inventor
Adam Geo
Goetschi Erwin
Mutel Vincent
Wichmann Juergen
Johannes Woltering Thomas
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20030792A2 publication Critical patent/HRP20030792A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20030792A 2001-04-12 2003-10-01 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HRP20030792A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109125 2001-04-12
PCT/EP2002/003644 WO2002083652A1 (en) 2001-04-12 2002-04-02 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II

Publications (1)

Publication Number Publication Date
HRP20030792A2 true HRP20030792A2 (en) 2005-10-31

Family

ID=8177126

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030792A HRP20030792A2 (en) 2001-04-12 2003-10-01 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II

Country Status (38)

Country Link
US (1) US6544985B2 (sh)
EP (1) EP1379511B1 (sh)
JP (1) JP4071115B2 (sh)
KR (1) KR100566171B1 (sh)
CN (1) CN1264825C (sh)
AR (1) AR035816A1 (sh)
AT (1) ATE299868T1 (sh)
AU (1) AU2002312788B2 (sh)
BG (1) BG108254A (sh)
BR (1) BR0208891A (sh)
CA (1) CA2442557C (sh)
CZ (1) CZ20033003A3 (sh)
DE (1) DE60205100T2 (sh)
DK (1) DK1379511T3 (sh)
EC (1) ECSP034797A (sh)
ES (1) ES2246012T3 (sh)
GT (1) GT200200073A (sh)
HK (1) HK1068888A1 (sh)
HR (1) HRP20030792A2 (sh)
HU (1) HUP0400851A3 (sh)
IL (2) IL157873A0 (sh)
JO (1) JO2285B1 (sh)
MA (1) MA27012A1 (sh)
MX (1) MXPA03009311A (sh)
MY (1) MY140271A (sh)
NO (1) NO20034576L (sh)
NZ (1) NZ528315A (sh)
PA (1) PA8543301A1 (sh)
PE (1) PE20021041A1 (sh)
PL (1) PL367064A1 (sh)
PT (1) PT1379511E (sh)
RU (1) RU2263112C2 (sh)
SI (1) SI1379511T1 (sh)
SK (1) SK13682003A3 (sh)
UY (1) UY27258A1 (sh)
WO (1) WO2002083652A1 (sh)
YU (1) YU79003A (sh)
ZA (1) ZA200307243B (sh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3886805B2 (ja) * 1999-10-15 2007-02-28 エフ.ホフマン−ラ ロシュ アーゲー ベンゾジアゼピン誘導体
PL208123B1 (pl) * 2001-12-27 2011-03-31 Taisho Pharmaceutical Co Ltd Pochodna kwasu 2-amino-3-alkoksy-6-fluorobicyklo [3.1.0] heksano-2, 6-dikarboksylowego, zawierająca ją kompozycja farmaceutyczna i lek, oraz jej zastosowanie
EP1925614A1 (en) * 2002-03-28 2008-05-28 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
MXPA04009332A (es) 2002-03-28 2005-12-12 Wisys Technology Found Inc Agentes ansioliticos con efectos sedantes y ataxicos.
PT1651234E (pt) * 2003-07-25 2007-12-28 Hoffmann La Roche Combinação de um antagonista de mglur2 e de um inibidor de ache para tratamento de perturbações neurólgicas agudas e/ou crónicas
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
CA2597608C (en) 2005-02-11 2013-12-24 F. Hoffmann-La Roche Ag Pyrazolo-pyrimidine derivatives as mglur2 antagonists
ES2339477T3 (es) 2005-03-23 2010-05-20 F.Hoffmann-La Roche Ag Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2.
MX351820B (es) 2005-06-23 2017-10-30 Astrazeneca Ab Proceso para preparar compuestos de bencimidazol.
CA2623721C (en) 2005-09-27 2014-05-13 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
GB0600228D0 (en) * 2006-01-06 2006-02-15 Fermentas Uab Inactivation method
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200808751A (en) * 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
AU2007299129A1 (en) 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
KR101151993B1 (ko) 2007-04-19 2012-06-01 에프. 호프만-라 로슈 아게 다이하이드로-벤조[b][1,4]다이아제핀-2-온 설폰아미드 유도체
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
CA2698929C (en) * 2007-09-14 2016-01-19 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
RS51660B (en) 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`, 3`-DISUPSTITUATED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1`H- [1,4`] BIPYRIDINYL-2`-ONE
JP5433582B2 (ja) 2007-11-14 2014-03-05 ジャンセン ファーマシューティカルズ, インコーポレイテッド. イミダゾ[1,2−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
EP2346505B1 (en) 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430031B1 (en) 2009-05-12 2013-04-17 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2430022B1 (en) 2009-05-12 2013-11-20 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CN103140483B (zh) 2010-07-15 2015-06-24 拜耳知识产权有限责任公司 作为杀虫剂的新杂环化合物
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2701699B1 (en) * 2011-04-28 2019-10-16 The Broad Institute, Inc. Inhibitors of histone deacetylase
JP5790195B2 (ja) * 2011-06-22 2015-10-07 セントラル硝子株式会社 ピラゾール化合物の製造方法
EP2751095B1 (en) * 2011-08-29 2021-10-27 Sanford-Burnham Medical Research Institute Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
SG11201503192XA (en) 2012-10-23 2015-06-29 Hoffmann La Roche Mglu2/3 antagonists for the treatment of autistic disorders
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
DK2940014T3 (en) * 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
ES2932406T3 (es) 2014-03-07 2023-01-18 Biocryst Pharm Inc Pirazoles sustituidos como inhibidores de calicreína del plasma humano
MX2016013711A (es) * 2014-04-23 2017-01-13 Hoffmann La Roche Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
WO2015191630A1 (en) 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN108727345B (zh) * 2017-04-25 2023-06-27 广东东阳光药业有限公司 一种咪唑环中间体的制备方法
CN108586447B (zh) * 2018-01-19 2021-01-29 中国人民解放军第四军医大学 一种苯二氮杂卓化合物及其制备方法和应用
SG11202112684SA (en) * 2019-06-06 2021-12-30 Arcus Biosciences Inc Processes for preparing aminopyrimidine compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506440A (ja) * 1999-08-05 2003-02-18 プレサイエント ニューロファーマ インコーポレイテッド 中枢神経系に関連する疾患の処置のための1,4−ジアゼピン誘導体
PT1224174E (pt) * 1999-10-15 2004-01-30 Hoffmann La Roche Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato
JP3886805B2 (ja) * 1999-10-15 2007-02-28 エフ.ホフマン−ラ ロシュ アーゲー ベンゾジアゼピン誘導体

Also Published As

Publication number Publication date
BR0208891A (pt) 2004-04-20
HUP0400851A2 (hu) 2004-07-28
NO20034576L (no) 2003-11-12
US6544985B2 (en) 2003-04-08
PT1379511E (pt) 2005-10-31
DE60205100T2 (de) 2006-06-01
EP1379511A1 (en) 2004-01-14
MY140271A (en) 2009-12-31
GT200200073A (es) 2002-11-07
IL157873A (en) 2008-11-26
CZ20033003A3 (cs) 2004-05-12
ES2246012T3 (es) 2006-02-01
KR100566171B1 (ko) 2006-03-29
ZA200307243B (en) 2004-12-16
WO2002083652A1 (en) 2002-10-24
PE20021041A1 (es) 2002-11-19
KR20030087076A (ko) 2003-11-12
PL367064A1 (en) 2005-02-21
YU79003A (sh) 2006-05-25
JP4071115B2 (ja) 2008-04-02
EP1379511B1 (en) 2005-07-20
MXPA03009311A (es) 2004-02-12
HUP0400851A3 (en) 2010-03-29
CN1264825C (zh) 2006-07-19
ATE299868T1 (de) 2005-08-15
NO20034576D0 (no) 2003-10-10
CA2442557C (en) 2008-12-23
RU2003130637A (ru) 2005-04-10
ECSP034797A (es) 2003-12-01
DK1379511T3 (da) 2005-11-07
DE60205100D1 (de) 2005-08-25
HK1068888A1 (en) 2005-05-06
BG108254A (bg) 2004-09-30
UY27258A1 (es) 2002-10-31
CN1535266A (zh) 2004-10-06
NZ528315A (en) 2005-04-29
RU2263112C2 (ru) 2005-10-27
AR035816A1 (es) 2004-07-14
SI1379511T1 (en) 2005-10-31
JP2004529925A (ja) 2004-09-30
US20020193367A1 (en) 2002-12-19
PA8543301A1 (es) 2003-01-24
SK13682003A3 (sk) 2004-07-07
IL157873A0 (en) 2004-03-28
AU2002312788B2 (en) 2005-11-10
JO2285B1 (en) 2005-09-12
CA2442557A1 (en) 2002-10-24
MA27012A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
HRP20030792A2 (en) DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
US6548495B2 (en) Dihydro-benzo [B] [1,4] diazepin-2-one derivatives
AU2002312788A1 (en) Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as mGluR2 antagonists II
ES2215738T3 (es) Derivados de benzodiazepina como receptor de glutamato metabotropico.
AU2002310912A1 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I
RU45093U1 (ru) Пылеуловитель

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn